Targeted deletion of PD-1 in myeloid cells induces antitumor immunity
Laura Strauss(AVEO Oncology (United States)), Vassiliki A. Boussiotis(Beth Israel Deaconess Medical Center), Rinku Pal(Beth Israel Deaconess Medical Center), John M. Asara(Beth Israel Deaconess Medical Center), Nikolaos Patsoukis(Beth Israel Deaconess Medical Center), Min Yuan(Tongji University), Anthos Christofides(Beth Israel Deaconess Medical Center), Qi Wang(Jilin University), Jessica D. Weaver(Beth Israel Deaconess Medical Center), Natalia M. Tijaro-Ovalle(Beth Israel Deaconess Medical Center), Mohamed A. A. Mahmoud(Ain Shams University)
Cited by 448
Related Papers
HIFα Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O <sub>2</sub> Sensing
|Science|2001|4.7k
PD-L2 is a second ligand for PD-1 and inhibits T cell activation
|Nature Immunology|2001|3k
Oncogenic Kras Maintains Pancreatic Tumors through Regulation of Anabolic Glucose Metabolism
|Cell|2012|2k
Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway
|New England Journal of Medicine|2016|1.4k
PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation
|Nature Communications|2015|1.2k